author-photo

David G. Maloney

Fred Hutchinson Cancer Research Center
University of Washington
National Institutes of Health

648

Papers

36073

Citations

Citation Trend

Filter By

Papers (648) Sort By

Journal Conference Others

Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.

2021 Hematology-oncology Clinics of North America
- Mazyar Shadman
- David G. Maloney
Show All
- Source
- Cite
- Save
Citations (0)
Multifocal Not Single-Site FDG-PET Residual Disease Prior to Autologous Stem Cell Transplant for Hodgkin Lymphoma Associated with Adverse Outcome

2021
Show All
- Source
- Cite
- Save
Citations (0)
Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Mega-dose 90Y-Ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma.

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (0)
IL-15 Serum Concentrations and CD19 CAR T-Cell Therapy: Impact on Clinical Outcomes and In Vivo CAR T Cell Kinetics

2021
Show All
- Source
- Cite
- Save
Citations (0)
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy.

2021 medRxiv
Show All
- Source
- Cite
- Save
Citations (2)
Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access (EA) and Commercial out-of-Specification (OOS) Product

2021
Show All
- Source
- Cite
- Save
Citations (0)